KARYOPHARM THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.06 USD | 0.00% |
|
-9.40% | +22.54% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,204 | 1,139 | 485.8 | 384.9 | 99.07 | 123.5 | - | - |
| Enterprise Value (EV) 1 | 1,204 | 983.8 | 426.4 | 277.1 | 99.07 | 197.5 | 123.5 | 123.5 |
| P/E ratio | -5.95 x | -5.69 x | -3.9 x | -1.68 x | -0.69 x | -0.87 x | -1.01 x | -1.77 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 29.4 x | 10.5 x | 2.32 x | 2.45 x | 0.68 x | 0.84 x | 0.75 x | 0.53 x |
| EV / Revenue | 29.4 x | 9.1 x | 2.03 x | 1.76 x | 0.68 x | 1.35 x | 0.75 x | 0.53 x |
| EV / EBITDA | -6,392,346 x | -5,757,400 x | -4,374,637 x | -1,956,921 x | - | - | - | - |
| EV / FCF | -6,301,093 x | -6,134,301 x | -3,973,319 x | -1,851,133 x | - | - | - | - |
| FCF Yield | -0% | -0% | -0% | -0% | - | - | - | - |
| Price to Book | 25.2 x | 22.1 x | -6.07 x | -16.7 x | - | - | - | - |
| Nbr of stocks (in thousands) | 62,790 | 73,601 | 75,547 | 113,213 | 114,534 | 116,466 | - | - |
| Reference price 2 | 19.17 | 15.48 | 6.430 | 3.400 | 0.8650 | 1.060 | 1.060 | 1.060 |
| Announcement Date | 2/13/20 | 2/11/21 | 2/8/22 | 2/15/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 40.89 | 108.1 | 209.8 | 157.1 | 146 | 146.5 | 164.7 | 231.2 |
| EBITDA | -188.3 | -170.9 | -97.48 | -141.6 | - | - | - | - |
| EBIT 1 | -189.3 | -171.8 | -98.27 | -142.2 | -129.5 | -129 | -125.1 | -87.27 |
| Operating Margin | -462.85% | -159% | -46.84% | -90.53% | -88.71% | -88.06% | -75.94% | -37.74% |
| Earnings before Tax (EBT) 1 | -199.6 | -196 | -123.8 | -164.9 | -142.8 | -148.1 | -193.3 | -108.7 |
| Net income 1 | -199.6 | -196.3 | -124.1 | -165.3 | -143.1 | -145.7 | -182 | -108.7 |
| Net margin | -488.08% | -181.59% | -59.14% | -105.23% | -97.99% | -99.44% | -110.47% | -47.02% |
| EPS 2 | -3.220 | -2.720 | -1.650 | -2.020 | -1.250 | -1.225 | -1.050 | -0.6000 |
| Free Cash Flow | -191 | -160.4 | -107.3 | -149.7 | - | - | - | - |
| FCF margin | -467.14% | -148.38% | -51.15% | -95.29% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/13/20 | 2/11/21 | 2/8/22 | 2/15/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 37.69 | 126.3 | 47.67 | 39.68 | 36.14 | 33.58 | 38.7 | 37.58 | 36.01 | 33.75 | 34.47 | 36.42 | 37.48 | 38.15 | 44.49 |
| EBITDA | -43.63 | 47.1 | -34.41 | -36.6 | -30.66 | -33.76 | -30.61 | -29.49 | -31.18 | - | - | - | - | - | - |
| EBIT 1 | -43.81 | 46.96 | -34.59 | -42.91 | -30.84 | -33.87 | -30.9 | -29.57 | -31.26 | -37.81 | -33.53 | -31.89 | -31.32 | -32.29 | -22.52 |
| Operating Margin | -116.25% | 37.19% | -72.55% | -108.14% | -85.32% | -100.86% | -79.85% | -78.7% | -86.81% | -112.03% | -97.25% | -87.56% | -83.58% | -84.66% | -50.63% |
| Earnings before Tax (EBT) 1 | -51.71 | 38.6 | -41.27 | -48.94 | -36.28 | -38.43 | -34.07 | -32.5 | -34.49 | -41.71 | -39.25 | -37.34 | -35.25 | -36.25 | - |
| Net income 1 | -51.81 | 38.72 | -41.4 | -49.06 | -36.32 | -38.51 | -34.13 | -32.63 | -34.51 | -41.84 | -39.94 | -37.28 | -34.49 | -33.99 | - |
| Net margin | -137.47% | 30.66% | -86.84% | -123.65% | -100.5% | -114.67% | -88.19% | -86.83% | -95.83% | -123.97% | -115.86% | -102.37% | -92.02% | -89.1% | - |
| EPS 2 | -0.6900 | 0.4600 | -0.5300 | -0.6200 | -0.4500 | -0.4300 | -0.3000 | -0.2900 | -0.3000 | -0.3600 | -0.3475 | -0.3225 | -0.3000 | -0.2625 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 2/8/22 | 5/5/22 | 8/4/22 | 11/3/22 | 2/15/23 | 5/4/23 | 8/2/23 | 11/2/23 | 2/29/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 74 | - | - |
| Net Cash position 1 | - | 156 | 59.3 | 108 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -191 | -160 | -107 | -150 | - | - | - | - |
| ROE (net income / shareholders' equity) | -171% | -391% | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -62.7% | -64.6% | -40.1% | -49.8% | - | - | - | - |
| Assets 1 | 318.1 | 304 | 309.2 | 331.7 | - | - | - | - |
| Book Value Per Share | 0.7600 | 0.7000 | -1.060 | -0.2000 | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 0.21 | 0.15 | 0.21 | 0.12 | - | - | - | - |
| Capex / Sales | 0.5% | 0.13% | 0.1% | 0.08% | - | - | - | - |
| Announcement Date | 2/13/20 | 2/11/21 | 2/8/22 | 2/15/23 | 2/29/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.06
USD
Average target price
5.571
USD
Spread / Average Target
+425.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.54% | 123M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- KPTI Stock
- Financials Karyopharm Therapeutics Inc.
